AVEO Pharmaceuticals — Investor Presentation (March 2014)
13 slides from AVEO Pharmaceuticals's investor presentation, Mar 13, 2014
Slide 1: 2014 Strategic Plan
2014 Strategic Plan 1 MARCH 13, 2014 Exhibit 99.2
Slide 2: Strategy Focused on Value Creation
Value Creation Internal Resources GDF-15 Platform Tivozanib AV-203 Ficlatuzumab Partnering Additional Opportunistic Strategic Initiatives A Strategy Focused on Value Creation
Slide 3: Clinical Stage Assets Value to be Realized through Partnerships
Clinical Stage Assets Value to be Realized through Partnerships
Slide 4: Clinical Status Development Plans: AV-203
March 13, 2014 Clinical Status Development Plans AV-203: ErbB3 Inhibitory Antibody Phase 1 dose-escalation study completed; AV-203 well-tolerated and recommended Phase 2 dose identified CLIA validation completed for patient selection biomarker with response observed in biomarker positive patients Da
Slide 5: Clinical Status Development Plans: Ficlatuzumab
March 13, 2014 Clinical Status Development Plans Ficlatuzumab: c-Met/HGF Inhibitory Antibody • Phase 2 study of ficlatuzumab in combination with gefitinib vs. gefitinib monotherapy in NSCLC completed in 2012 • Exploratory analysis identified a patient subpopulation deriving benefit from ficlatuzumab
Slide 6: Clinical Status Development Plans: Tivozanib
March 13, 2014 Clinical Status Development Plans Tivozanib: Triple VEGFR Inhibitory Small Molecule Wind down discontinued trials of tivozanib in RCC, colorectal and triple negative breast cancers 150 patients elected to remain on study (primarily RCC & CRC) Remaining committed costs shared with Aste
Slide 7: AV-380 in Cachexia A Major Opportunity
AV-380 in Cachexia A Major Opportunity
Slide 8: ~400,000 cancer cachexia patients in major markets
~400,000 cancer cachexia patients in 7 major markets 2 What is Cachexia and Who Does it Affect? Cachexia : Complex metabolic syndrome associated with several underlying chronic illnesses and characterized by loss of muscle mass and strength, loss of whole body fat, inflammation, anemia, etc. % preva
Slide 9: GDF-15 – Key Mediator of Cancer Induced Cachexia
GDF-15 – Key Mediator of Cancer Induced Cachexia • Discovered through AVEO’s Human Response Platform TM – Key tumor signaling pathway identified whose activation triggers a genetic program that results in cachexia – GDF-15 identified as the key mediator – GDF-15 is a soluble factor found in serum/pl
Slide 10: AV-380 – A First-in-Class Opportunity
AV-380 – A First-in-Class Opportunity • AV-380: Potent humanized GDF-15 inhibitory Mab – Unique mechanism of action that addresses multiple, key underlying mechanisms of cachexia with the potential to • Increase calorie/food intake • Reverse body weight loss • Restore normal body composition • Mecha
Slide 11: Potential Beyond Cancer Cachexia
17 AV-380 Congestive Heart Failure Cancer Chronic Kidney Disease Chronic Obstructive Pulmonary Disease Cancer Potential Beyond Cancer Cachexia ~5M patients suffering from muscle wasting in the U.S. Initial Focus 1. Morley et al; Am J Clin Nutr 2006;83:735– Additional Cachexia Opportunities Cancer
Slide 12: Additional Opportunistic Strategic Initiatives
Additional Opportunistic Strategic Initiatives
Slide 13: Summary
Summary
AVEO Pharmaceuticals — Investor Presentation (March 2014) on 6ix